Cancer News and Research

Latest Cancer News and Research

ARIAD Pharmaceuticals' investigational pan-BCR-ABL inhibitor receives FDA and EMA orphan drug designation

ARIAD Pharmaceuticals, Inc. today announced that its investigational pan-BCR-ABL inhibitor, AP24534, has been granted orphan drug designation by both the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the U.S., the orphan designation of AP24534 is for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and in the E.U., its orphan designation is for CML and acute lymphoblastic leukemia.

2 Mar 2010

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Isis Pharmaceuticals, Inc. today announced its 2009 financial results and reviewed the highlights of the year. Isis achieved its 2009 financial guidance with pro forma net income of $166.9 million and a pro forma net operating loss (NOL) of $14.2 million compared with its guidance for the year of pro forma net income of more than $145 million and a pro forma NOL in the low to mid $20 million range. Isis also achieved its cash guidance by ending 2009 with $574.3 million of cash, cash equivalents and short-term investments significantly in excess of the $550 million projected.

1 Mar 2010

COMP issues positive opinion for Æterna Zentaris' perifosine orphan medicinal product designation

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation for its compound perifosine from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for the treatment of multiple myeloma.

1 Mar 2010

AMAG Pharmaceuticals reports fourth-quarter 2009 net product revenues of $12.8M attributable to Feraheme

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2009.

1 Mar 2010

Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment

OncoGenex Pharmaceuticals, Inc., announced today that two peer-reviewed articles have been published that further elucidate the biological function of clusterin, its role in promoting tumor resistance to cancer treatment, and the role of an inhibitor of clusterin such as custirsen (OGX-011) that is designed to knock down treatment resistance in the cells and enhance the effectiveness of cancer therapies.

1 Mar 2010

Astellas Pharma to acquire OSI Pharmaceuticals for $3.5 billion on fully diluted basis

Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.

1 Mar 2010

Study compares advertising tactics between indoor tanning and tobacco industries to market unhealthy products

While the proven negative health consequences of smoking and tanning are undeniable, tobacco and indoor tanning advertisers would like consumers to think otherwise. In fact, a new study comparing the tactics used in advertising tobacco and indoor tanning products found several similarities in how these two industries market unhealthy products.

1 Mar 2010

SUVmax in head and neck squamous cell carcinoma patients predict overall survival

The maximal standardized uptake value (called SUVmax) measured from FDG PET readings taken from the primary tumor in head and neck squamous cell carcinoma patients before treatment is a strong predictor of disease-specific survival, overall survival and disease-free survival, while pretreatment SUVmax for lymphodenopathy is strongly associated with distant metastasis, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

1 Mar 2010

Determining personal risk for genetic disorders essential

Genetic diseases affect an estimated 12 million Americans, yet according to a survey of 1,000 people conducted by the Genetic Disease Foundation (GDF), while two-thirds of those surveyed were willing to and saw the benefits of undergoing genetic testing, close to 80 percent had never talked to their physician about genetic screening – an inconsistency that can have serious implications on a person's overall health and the health of their immediate family members.

1 Mar 2010

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

SIMPLE Antibody(TM) Platform Delivers Unprecedented Choice of Ultra-Potent Functional Antibody Leads Against Challenging Soluble and Cell Surface Targets. - ARGX-109, a Fully Human mAb Targeting Autoimmune, Inflammation and Oncology Indications, Enters Preclinical Development in Less Than 12 Months From Start of Discovery.

1 Mar 2010

Researchers figure out how ATP molecule broken down in cells

Researchers at the Louisiana State University Health Sciences Center have figured out how ATP is broken down in cells, providing for the first time a clear picture of the key reaction that allows cells in all living things to function and flourish.

1 Mar 2010

Study evaluates possible diet associations with ovarian cancer survival

2009 estimates projected that in the United States alone 21,550 new cases of ovarian cancer would be diagnosed and 14,600 women would die of the disease. Often diagnosed in late stages, ovarian cancer has an asymptomatic onset and a relatively low 5-year survival rate of about 45%. Consequently investigation linked to survivorship is critical.

1 Mar 2010

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

The Board of Directors of Ipsen, chaired by Jean-Luc Bélingard, met on 26 February 2010 to review the Group’s results for 2009, published today.

1 Mar 2010

New method using SGR to calculate rate of tumour growth developed

When treating cancer, it is an advantage to know the rate of growth of the cancer tumour. The standard method currently used to determine tumour growth, however, is erroneous. This is the conclusion of scientists at the University of Gothenburg, Sweden, who have developed a new model.

1 Mar 2010

Breastfeeding and better hygiene may protect against peptic ulcer bacterium infection

Young children in developing countries are infected at an early age with the bacterium Helicobacter pylori, which can cause peptic ulcers and stomach cancer. New findings show that childrens´ immune responses help in fighting the bacteria. In addition, breastfeeding and better hygiene appear to protect against infection. The results provide hope for a vaccine, according to research from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

1 Mar 2010

Aprepitant drug can reduce nausea and vomiting when combined with other anti-nausea drugs

Bone marrow transplant patients say two of the most debilitating side effects of the treatment are nausea and vomiting caused by chemotherapy and radiation.

1 Mar 2010

ADVENTRX' ANX-530 NDA: FDA issues refuse to file letter

ADVENTRX Pharmaceuticals, Inc. announced today that it received a refuse to file letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion). In the letter, the FDA indicated that the data included in the initial submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. FDA identified only the one chemistry, manufacturing and controls (CMC) reason for the refusal to file. ADVENTRX plans to meet with the FDA as soon as possible to discuss its response.

1 Mar 2010

Childhood obesity prevention: Prenatal and infancy period upto age 5 crucial

Efforts to prevent childhood obesity should begin far earlier than currently thought-perhaps even before birth-especially for minority children, according to a new study that tracked 1,826 women from pregnancy through their children's first five years of life.

1 Mar 2010

Short-term dose of losartan-M6PHSA reduces liver inflammation and fibrosis: Study

A recent study found that rats with advanced fibrosis that were administered a short-term dose of losartan-M6PHSA had reduced liver inflammation and fibrosis. Those animals treated with oral losartan alone did not experience a similar reduction in disease activity. Results of this study appear in the March issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

1 Mar 2010

Growth rate among non-radiologists who own/lease PET equipment is on the rise: Study

Just as with computed tomography (CT) and magnetic resonance imaging (MRI), the growth rate among non-radiologists who own or lease positron emission tomography (PET) equipment is also on the rise, contributing significantly to the ongoing issues surrounding self-referral and unnecessary utilization of imaging in the United States, according to a study published in the March issue of the Journal of the American College of Radiology (www.jacr.org)

1 Mar 2010

Cancer News and Research

Latest Cancer News and Research

ARIAD Pharmaceuticals' investigational pan-BCR-ABL inhibitor receives FDA and EMA orphan drug designation

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

COMP issues positive opinion for Æterna Zentaris' perifosine orphan medicinal product designation

AMAG Pharmaceuticals reports fourth-quarter 2009 net product revenues of $12.8M attributable to Feraheme

Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment

Astellas Pharma to acquire OSI Pharmaceuticals for $3.5 billion on fully diluted basis

Study compares advertising tactics between indoor tanning and tobacco industries to market unhealthy products

SUVmax in head and neck squamous cell carcinoma patients predict overall survival

Determining personal risk for genetic disorders essential

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

Researchers figure out how ATP molecule broken down in cells

Study evaluates possible diet associations with ovarian cancer survival

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

New method using SGR to calculate rate of tumour growth developed

Breastfeeding and better hygiene may protect against peptic ulcer bacterium infection

Aprepitant drug can reduce nausea and vomiting when combined with other anti-nausea drugs

ADVENTRX' ANX-530 NDA: FDA issues refuse to file letter

Childhood obesity prevention: Prenatal and infancy period upto age 5 crucial

Short-term dose of losartan-M6PHSA reduces liver inflammation and fibrosis: Study

Growth rate among non-radiologists who own/lease PET equipment is on the rise: Study

Understanding the DNA Damage Response in Innate Immunity eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in